Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697999 | 0.98 | LMNA (0.48) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL698775 | 0.94 | LMNA (0.44) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL698071 | 0.89 | — | — | |
| SCHEMBL1669840 | 0.87 | LMNA (0.59) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL23129641 | 0.85 | LMNA (0.57) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL1672623 | 0.84 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL696997 | 0.82 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL6032436 | 0.81 | LMNA (0.53) | LMNASLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL698469 | 0.80 | EPHX1 (0.42) | LMNAEPHX1HPGDNAAA | |
| SCHEMBL25381860 | 0.80 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0295100-B1 | Methoxymethyl compounds | ERBA CARLO SPA (IT) | 1994-09-14 | — | — | EP | claimed |
| US-4952577-A | ANTIBIOTICS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-08-28 | — | — | US | claimed |
| EP-0295100-A1 | Methoxymethyl compounds | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-12-14 | — | — | EP | claimed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2097079-B1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER FLEMING LTD (GB) | 2012-06-27 | — | — | EP | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20110166118-A1 | NEW TRINEM ANTIBIOTICS AND INHIBITORS OF BETA-LACTAMASES | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-07 | — | — | US | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307415-A1 | NEW TRINEM ANTIBIOTICS AND INHIBITORS OF BETA-LACTAMASES | LEK Pharmaceuticals d.d. (SI) | 2011-04-13 | — | — | EP | disclosed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | LMNA 4436/4885SLC1A3 3327/4885SLC1A2 2104/4885 |
| US-20110166118-A1 | NEW TRINEM ANTIBIOTICS AND INHIBITORS OF BETA-LACTAMASES | MGAM, TMSB10, MRPL21 | LMNA 2002/4885SLC1A3 4862/4885SLC1A2 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.